Antimicrobial surveillance in idiopathic parkinsonism: Indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity

Helicobacter

Volumn 18, Issue 3, 2013, Pages 187-196

  Dobbs, Sylvia M ^a,b,c   Charlett, André ^a,d   John Dobbs, R ^a,b,c   Weller, Clive ^a   Iguodala, Owens ^b   Smee, Cori ^b   Lawson, Andrew J ^d   Taylor, David ^a,b   Bjarnason, Ingvar ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Antimicrobials; Facets of Parkinson's disease; Helicobacter; Pathogenic pathways; Small intestinal bacterial overgrowth

Indexed keywords

ANTIINFECTIVE AGENT; ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL OVERGROWTH; DRUG HALF LIFE; DRUG SURVEILLANCE PROGRAM; FEMALE; FLEXOR MUSCLE; FLUID INTAKE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYDROGEN BREATH TEST; HYPOKINESIA; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; NONHUMAN; PARKINSONISM; PATHOGEN CLEARANCE; PRESCRIPTION; PRIORITY JOURNAL; STOMACH BIOPSY; TREMOR; WALKING SPEED;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIPARKINSON AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYPOKINESIA; INTESTINE, SMALL; LEVODOPA; MALE; MIDDLE AGED; MUSCLE RIGIDITY; PARKINSONIAN DISORDERS; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); HELICOBACTER; HELICOBACTER PYLORI;

EID: 84876989267     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12035     Document Type: Article

References (32)

1. Dobbs RJ, Dobbs SM, Weller C et al. Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter 2008;13:309-22.
2. Dobbs SM, Dobbs RJ, Weller C et al. Differential effect of Helicobacter pylori eradication on time trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Report on Completion of a randomised, double-blind, placebo-controlled efficacy study. Helicobacter 2010;15:279-94.
3. Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2011;26:889-92.
4. Dobbs RJ, Charlett A, Dobbs SM et al. Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathogens 2012;4:12.
5. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32(Suppl):125-7.
6. Weller C, O'Neill CJA, Charlett A, Bowes SG, Purkiss A, Nicholson PW, Dobbs RJ, Dobbs SM. Defining small differences in efficacy between anti-Parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor. Br J Clin Pharmacol 1993;35:379-85.
7. Kirollos C, Charlett A, Bowes SG et al. Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism. Eur J Clin Pharmacol 1996;50:7-18.
8. Charlett A, Weller C, Purkiss A, Dobbs SM, Dobbs RJ. Breadth of base whilst walking: effect of ageing and parkinsonism. Age Ageing 1998;27:49-54.
9. Elviss NC, Owen RJ, Xerry J, Walker AM, Davies K. Helicobacter pylori resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. J Antimicrob Ther 2004;54:435-40.
10. Ho SA, Hoyle JA, Lewis FA et al. Direct polymerase chain reaction test for detection of Helicobacter pylori in humans and animals. J Clin Microbiol 1991;29:2543-9.
11. Chisholm SA, Owen RJ, Teare EL, Saverymuttu S. PCR-based diagnosis of Helicobacter pylori infection and real-time determination of clarithromycin resistance directly from human gastric biopsy samples. J Clin Microbiol 2001;39:1217-20.
12. Rhodes JM, Middleton P, Jewell DP. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial over-growth. Scand J Gastroenterol 1979;14:333-6.
13. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003;2:107-16.
14. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011;60:334-40.
15. Abu-Shanab A, Quigley EMM. Diagnosis of small intestinal bacterial overgrowth: the challenges persist. Expert Rev Gastroenterol Hepatol 2009;3:77-87.
16. Sipponen P, Kosunen TU, Samloff IM, Heinonen OP, Siurala M. Rate of Helicobacter pylori acquisition among Finnish adults: a fifteen year follow-up. Scand J Gastroenterol 1996;31:229-32.
17. StataCorp. Stata: Release 12. Statistical Software. College Station, TX: StataCorp LP, 2011.
18. Akiake Y. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19:716-23.
19. Wald A. Tests of statistical hypotheses concerning several parameters when the number of observations is large. Trans Am Math Soc 1943;54:426-82.
20. Charlett A, Dobbs RJ, Purkiss AG, Weller C, Peterson DW, Dobbs SM. Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol Scand 1998;97:77-85.
21. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-a and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999;100:34-41.
22. Bowes SG, Dobbs RJ, Henley M, Charlett A, O'Neill CJ, Nicholson PW, Purkiss AG, Weller C, Dobbs SM. Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa. Eur J Clin Pharmacol 1992;43:483-9.
23. Pfeiffer RF. Neuroinflammation and Parkinson disease: the silent battleground. Neurology 2009;73:1434-5.
24. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric a-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72.
25. Kupsky WJ, Grimes MM, Sweeting J, Bectsch R, Cote LJ. Parkinson's disease and megacolon: hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987;37:1253-5.
26. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Gastroenterology 1984;87:848-56.
27. Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, Quigley EM. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995;346:861-4.
28. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy-body containing neurons in the enteric nervous system. Acta Neuropathol 1990;79:581-3.
29. Charlett A, Dobbs RJ, Weller C, Dobbs SM. Stasis in the gut: the source of xenobiotic in idiopathic parkinsonism. Eur J Clin Pharmacol 1997;52(Suppl):168.
30. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-62.
31. Charlett A, Dobbs RJ, Dobbs SM et al. Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease. Gut Pathogens 2009;1:20.
32. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61:918-32.